1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T 1984 Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823

2. Yu CM, Sanderson JE 1999 Plasma brain natriuretic peptide--an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1:59-65

3. Cruden NLM, Witherow FN, Webb DJ, Fox KAA, Newby DE 2004 Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure. Arterioscler Thromb Vasc Biol 24:1043-1048

4. Erdmann E, Lechat P, Verkenne P, Wiemann H 2001 Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3:469-479

5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial 1999 Lancet 353:9-13

6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717

7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators 2003 Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 348:1309-1321

8. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Ephesus investigators. Serum potassium and clinical outcomes in the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118(16):1643-1650

9. The Heart Outcomes Prevention Evaluation Study Investigators 2000 Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 342:145-153

10. Fujiwara Y, Shiraya S, Miyake T, Yamakawa S, Aoki M, Makino H, Nishimura M, Morishita R 2008 Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 22(6):703-708

11. Dai Q, Xu M, Yao M, Sun B 2007 Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 152(7):1042-1048

12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEJM 351(13):1296-1305

13. Porsti IH. Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney. Kidney Int 2008;74(11):1371-1373

14. Richart T, Li Y, Staessen JA. Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am J Hypertens 2007;20(9):1007-1015

15. Pliquett R, Fasshauer M, Bluher M, Paschke R 2004 Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol 3:4

16. Expert Panel on Detection EaToHBCiA 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497

17. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J 2003 Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419

18. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359(20):2105-2120

19. Lindholm LH, Ibsen H, Borch J, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de F, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe P, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, 2002 Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20:1879-1886

20. Sabatine MS, Morrow DA, de L, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E 2002 Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105:1760-1763

21. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; the JUPITER Study Group 2008 Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 359 (21):2195-2207

22. Heart Protection Study Collaborative Group 2002 MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 6;360(9326):23-33

23. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, Daniel WG 1999 Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215-222

24. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz V, Ocampo ON, Eng C 1999 Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651

25. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G 2001 Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104:982-985

26. Stalcup SA, Davidson D, Mellins RB 1982 Endothelial cell functions in the hemodynamic responses to stress. Ann N Y Acad Sci 401:117-131

27. Vischer UM, Wollheim CB 1997 Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb Haemost 77:1182-1188

28. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG 2000 Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 86:347-354

29. Schade R, Gohler K, Burger W, Hirschelmann R 1987 Modulation of rat C-reactive protein serum level by dexamethasone and adrenaline--comparison with the response of alpha 2-acute phase globulin. Agents Actions 22:280-287

30. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB 2002 betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297:843-845

31. Aizawa T, Ishizaka N, Usui S, Ohashi N, Ohno M, Nagai R 2002 Angiotensin II and catecholamines increase plasma levels of 8-epi-prostaglandin F(2alpha) with different pressor dependencies in rats. Hypertension 39:149-154

32. De L, Terreni L, Sironi M, De S 1998 The sympathetic nervous system tonically inhibits peripheral interleukin-1beta and interleukin-6 induction by central lipopolysaccharide. Neuroscience 83:1245-1250

33. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC 1998 Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274:H1684-H1689

34. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, Kugiyama K, Ogawa H, Okumura K, Ogawa Y, Nakao K 1996 Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 132:101-107

35. Morita H, Nishida Y, Motochigawa H, Kangawa K, Minamino N, Matsuo H, Hosomi H 1989 Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits. Am J Physiol 256:R792-R796

36. Kambayashi Y, Nakao K, Kimura H, Kawabata T, Nakamura M, Inouye K, Yoshida N, Imura H 1990 Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun 173:599-605

37. Brugger-Andersen T, Ponitz V, Staines H, Pritchard D, Grundt H, Nilsen DW. B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas hsCRP predicts short-term ischemic events in coronary chest pain patients: a prognostic study. BMC Cardiovasc Disord 2008;8(1):34

38. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, Redfield MM, Burnett JC 2002 The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 8:149-154

39. Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 2008-11-29

40. Huang Y, Noble NA, Zhang J, Xu C, Border WA 2007 Renin-stimulated TGF-beta 1 expression is regulated by mitogen-activated protein kinase in renal mesangial cells. Kidney International 72:45–52

41. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Danser AHJ, Nguyen G. 2008 Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-2)27 rats. Hypertension 52:130-136

42. Roks AJ, van G, Pinto YM, Buikema H, Henning RH, de Z, van G 1999 Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 34:296-301

43. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM 1992 In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19:692-696

44. Barton M, Shaw S, Uscio LV, Moreau P, Luscher TF 1997 Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238:861-865

45. Browatzki M, Schmidt J, Kubler W, Kranzhofer R 2000 Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 95:98-105

46. Zucker IH, Wang W, Pliquett RU, Liu JL, Patel KP 2001 The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann N Y Acad Sci 940:431-443

47. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators 2008 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):511-512

48. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K 2001 Aldosterone production is activated in failing ventricle in humans. Circulation 103:72-77

49. Gomez-Sanchez CE, Gomez-Sanchez EP 2001 Editorial: Cardiac steroidogenesis-new sites of synthesis, or much ado about nothing ? J Clin Endocrinol Metab 86(11): 5121- 5126

50. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008;29(2):133-154

51. Orth D.N., Kovacs W.J. 1998 The adrenal cortex. In “Williams Textbook of Endocrinology”. 9th edition; WB Saunders, Philadelphia

52. Weber KT 2001 Aldosterone in congestive heart failure. N Engl J Med 345:1689-1697

53. Losel RM, Feuring M, Falkenstein E, Wehling M 2002 Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 67:493-498

54. Rocha R, Williams GH 2002 Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 62:723-731

55. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T, Matsubara H 2008 Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 1(2):363-375

56. Godfrey V, Farquharson CA, Macdonald JE, Yee KM, Struthers AD 2007 Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cariol 117(2):282-284

57. Funder JW, Mihailaidou AS. Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol 2008

58. Di Zhang A, Cat AN, Soukaseium C, Escoubet B, et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008; 52(6):1060-1067

59. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH 2001 Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 280:R1906-R1913

60. Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC 2001 The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 38 Suppl 2:S49-S52

61. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial 1996 JAMA 275:370-375

62. Hunt BE, Davy KP, Jones PP, DeSouza CA, Van P, Tanaka H, Seals DR 1997 Systemic hemodynamic determinants of blood pressure in women: age, physical activity, and hormone replacement. Am J Physiol 273:H777-H785

63. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, 2002 Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49-57

64. Writing Group for the Women's Health Initiative Investigators 2002 Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333

65. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML; WHI and WHI-CACS Investigators 2007 Estrogen therapy and coronary-artery calcification. NEJM 356(25):2591-2602.

66. Committee on Gynecologic Practice. ACOG Committee opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol. 2008 Nov;112(5):1189-92

67. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA 2002 Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106:92-99

68. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH 2004 Superoxide Mediates Sympathoexcitation in Heart Failure: Roles of Angiotensin II and NAD(P)H Oxidase. Circ Res 95:937-944

69. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V 2004 C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. N Engl J Med 350:1387-1397

70. Ridker PM, Cook N 2004 Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation 109:1955-1959

71. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T 2001 Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2678

72. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008 Feb;34(1):2-11

73. Kralisch S, Sommer G, Deckert CM, Linke A, Bluher M, Stumvoll M, Fasshauer M. Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol. 2007 Sep;32(3):161-71

74. Rasouli N and Kern PA 2008 Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93:S64-S73